




The relative strengths and weaknesses of Cytomx Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytomx Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Cytomx Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 288%, being 25% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	189,754
Cost of Goods Sold	0
Intangible Assets	2,699
Liabilities, Current	15,739
Liabilities, Non-Current	198
Other Assets	1,281
Other Compr. Net Income	-76
Other Expenses	1,742
Other Liabilities	55,210
Other Net Income	-429
Other Revenues	7,712
Property and Equipment	3,481
Research and Development	28,357
Selling, General and Administrative Expense	12,558

Output Variable	Value in 1000 USD
Assets	197,215
Liabilities	71,147
Expenses	42,657
Revenues	7,712
Stockholders Equity	126,068
Net Income	-35,374
Comprehensive Net Income	-35,412
BaseVar	159,618
ECR before Limited Liability	178%
Economic Capital Ratio	288%